In early December, the 2025 updates of China’s NRDL were finalised with a total of 114 drugs, including Western drugs and ...

Outlook Therapeutics has received the US FDA's CRL regarding the BLA resubmission for ONS-5010/LYTENAVA to treat wet AMD.

Valneva and the Serum Institute of India (SII) have ended a license agreement for chikungunya vaccine supply in Asia after ...

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a ...

Data indicating unequal treatment effects in women has prompted calls for more nuance in Alzheimer’s diagnosis and drug ...

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.

Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the ...

Maryland’s Prescription Drug Affordability Board (PDAB) serves as a bellwether for how other states may address high drug ...

With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing ...

AstraZeneca's Andexxa will no longer be sold or manufactured in the US following FDA concerns around the drug's association ...

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but strategy is key in a ...